Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hartmut Goldschmidt

Showing results (251-260 of 539) with videos related to

Pageof 54
Sort By:
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|January 11, 2024
Sequence diversity of kappa light chains from patients with AL amyloidosis and multiple myelomaSarah Schreiner, Natalie Berghaus, Alexandra M Poos, et al.
Haematologica|July 1, 2026
<i>Erratum</i> to: "Isatuximab plus bortezomib, lenalidomide, and dexamethasone for transplant-ineligible newly diagnosed multiple myeloma patients: a frailty subgroup analysis of the IMROZ trial"Salomon Manier, Meletios-Athanasios Dimopoulos, Xavier P Leleu, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 22, 2007
Cancer/testis genes in multiple myeloma: expression patterns and prognosis value determined by microarray analysisMaud Condomines, Dirk Hose, Pierre Raynaud, et al.
American Journal of Hematology|April 12, 2021
Daratumumab, lenalidomide, and dexamethasone in systemic light-chain amyloidosis: High efficacy, relevant toxicity and main adverse effect of gain 1q21Christoph R Kimmich, Tobias Terzer, Axel Benner, et al.
Leukemia|April 25, 2020
Deepening responses associated with improved progression-free survival with ixazomib versus placebo as posttransplant maintenance in multiple myelomaHartmut Goldschmidt, Meletios A Dimopoulos, S Vincent Rajkumar, et al.
Journal of Hematology & Oncology|June 28, 2019
Prospective target assessment and multimodal prediction of survival for personalized and risk-adapted treatment strategies in multiple myeloma in the GMMG-MM5 multicenter trialDirk Hose, Susanne Beck, Hans Salwender, et al.
British Journal of Haematology|August 30, 2008
Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem-cell transplantation or conventional chemotherapy: results of a Phase I clinical trialWolfram Pönisch, Marta Rozanski, Hartmut Goldschmidt, et al.
Nature Communications|November 25, 2016
Multiple myeloma risk variant at 7p15.3 creates an IRF4-binding site and interferes with CDCA7L expressionNi Li, David C Johnson, Niels Weinhold, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|June 2, 2009
Melan-A/MART1 analog peptide triggers anti-myeloma T-cells through crossreactivity with HM1.24Olaf Christensen, Alaviana Lupu, Stefanie Schmidt, et al.
British Journal of Haematology|August 3, 2021
Lenalidomide and dexamethasone in relapsed/refractory immunoglobulin light chain (AL) amyloidosis: results from a large cohort of patients with long follow-upMarco Basset, Christoph R Kimmich, Nicholas Schreck, et al.
Pageof 54

Showing results (251-260 of 539) with videos related to

Sort By:
Pageof 54
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|January 11, 2024
Sequence diversity of kappa light chains from patients with AL amyloidosis and multiple myelomaSarah Schreiner, Natalie Berghaus, Alexandra M Poos, et al.
Haematologica|July 1, 2026
<i>Erratum</i> to: "Isatuximab plus bortezomib, lenalidomide, and dexamethasone for transplant-ineligible newly diagnosed multiple myeloma patients: a frailty subgroup analysis of the IMROZ trial"Salomon Manier, Meletios-Athanasios Dimopoulos, Xavier P Leleu, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 22, 2007
Cancer/testis genes in multiple myeloma: expression patterns and prognosis value determined by microarray analysisMaud Condomines, Dirk Hose, Pierre Raynaud, et al.
American Journal of Hematology|April 12, 2021
Daratumumab, lenalidomide, and dexamethasone in systemic light-chain amyloidosis: High efficacy, relevant toxicity and main adverse effect of gain 1q21Christoph R Kimmich, Tobias Terzer, Axel Benner, et al.
Leukemia|April 25, 2020
Deepening responses associated with improved progression-free survival with ixazomib versus placebo as posttransplant maintenance in multiple myelomaHartmut Goldschmidt, Meletios A Dimopoulos, S Vincent Rajkumar, et al.
Journal of Hematology & Oncology|June 28, 2019
Prospective target assessment and multimodal prediction of survival for personalized and risk-adapted treatment strategies in multiple myeloma in the GMMG-MM5 multicenter trialDirk Hose, Susanne Beck, Hans Salwender, et al.
British Journal of Haematology|August 30, 2008
Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem-cell transplantation or conventional chemotherapy: results of a Phase I clinical trialWolfram Pönisch, Marta Rozanski, Hartmut Goldschmidt, et al.
Nature Communications|November 25, 2016
Multiple myeloma risk variant at 7p15.3 creates an IRF4-binding site and interferes with CDCA7L expressionNi Li, David C Johnson, Niels Weinhold, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|June 2, 2009
Melan-A/MART1 analog peptide triggers anti-myeloma T-cells through crossreactivity with HM1.24Olaf Christensen, Alaviana Lupu, Stefanie Schmidt, et al.
British Journal of Haematology|August 3, 2021
Lenalidomide and dexamethasone in relapsed/refractory immunoglobulin light chain (AL) amyloidosis: results from a large cohort of patients with long follow-upMarco Basset, Christoph R Kimmich, Nicholas Schreck, et al.
Pageof 54